ACE2 Receptor‐Targeted Inhaled Nanoemulsions Inhibit SARS‐CoV‐2 and Attenuate Inflammatory Responses

• DOI: 10.1002/adma.202311537
• Publication Date: 2024-01-04T09:51:35Z
• Authors: Hairui Wang; Shuang Luo; Mingxin Xie; Zhao Chen; Yunming Zhang; Zhiqiang Xie; Yongshun Zhang; Yu Zhang; Lan Yang; Fuhua Wu; Xiaoyan Chen; Guangsheng Du; Jincun Zhao; Xun Sun
• Keywords: Coronavirus; Targeted drug delivery; Angiotensin-converting enzyme 2

Abstract Three kinds of coronaviruses are highly pathogenic to humans, and two them mainly infect humans through Angiotensin‐converting enzyme 2 （ACE2）receptors. Therefore, specifically blocking ACE2 binding at the interface with receptor‐binding domain is promising achieve both preventive therapeutic effects coronaviruses. Alternatively, drug‐targeted delivery based on receptors can further improve efficacy safety inhalation drugs. Here, these approaches innovatively combined by designing a nanoemulsion (NE) drug system (termed NE‐AYQ) for that targets receptors. This inhalation‐delivered remdesivir RDSV‐NE‐AYQ) effectively inhibits infection target cells wild‐type mutant viruses. The RDSV‐NE‐AYQ strongly Severe acute respiratory syndrome coronavirus dimensions: they not only block virus host cell surface but also restrict replication intracellularly. Furthermore, in mouse model lung injury, inhaled loaded anti‐inflammatory drugs (TPCA‐1‐NE‐AYQ) significantly alleviate tissue injury mice. smart combination provides new choice dealing possible emergencies future rapid development treatment diseases.